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The present work reports preparation of irbesartan (IBS) loaded nanofibre mats using electro-
spinning technique. The prepared nanofibres were characterized by scanning electron micro-
scopy, Fourier transform infrared spectroscopy, differential scanning calorimetry, X-ray
diffraction analysis, in vitro diffusion and ex vivo skin permeation studies. FTIR studies revealed
chemical compatibility of IBS and polyvinyl pyrrolidine (PVP K-30). SEM images confirmed
formation of nanofibres wherein IBS existed in amorphous form as revealed by DSC and






Transdermal drug deliveryXRD analyses. The prepared nanofibre mats of IBS were found to be superior to IBS loaded as
cast films when analysed for in vitro IBS release and ex vivo skin permeation studies since the
flux of IBS loaded nanofibres was 17 times greater than as cast film. The improvement in drug
delivery kinetics of IBS loaded nanofibres could be attributed to amorphization with reduction
in particle size of IBS, dispersion of IBS at molecular level in PVP matrix and enormous increase
in the surface area for IBS release due to nanonization. Thus transdermal patch of IBS loaded
nanofibres can be considered as an alternative dosage form in order to improve its biopharma-
ceutical properties and enhance therapeutic efficacy in hypertension.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
One of the commonest disorders responsible for cardiovascu-
lar mortality and morbidity in large population is hypertension
[1]. Various routes including oral and parenteral are reported
for delivery of drugs to the patients suffering from hyperten-
sion. In most of the cases, oral route is preferred over any
other routes of drug delivery owing to its advantages such as
ease of administration and patient compliance. However, the
oral drug delivery system also proposes drawbacks such as
uneven biodistribution of drug, lack of drug targeting and
specificity, requirement of large doses in order to achieve ther-
apeutic plasma drug levels and adverse side effects associated
with such high dose. The transdermal route of drug adminis-
tration can deliver drugs locally as well as into the systemic cir-
culation. Thus it is recognized as one of the potential routes of
drug delivery. Owing to the advantages such as bypassing first
pass effect, sustained drug release, reduced side effects with
frequency of drug administration and patient compliance,
transdermal drug delivery systems have attracted most of the
researchers [2].
Irbesartan (IBS) is BCS II drug with low solubility and high
permeability. It is primarily used for the treatment of cardio-
vascular diseases including hypertension, cardiac insufficiency
and cardiac arrhythmia [3,4]. It is an angiotensin II receptor
type 1 antagonist and also reported to delay progression of
diabetic nephropathy. Moreover, it is also indicated for the
reduction of renal disease progression in patients with type
II diabetes. However, its low solubility and in turn bioavail-
ability act as a hurdle in development of dosage form. Addi-
tionally, it shows side effects such as the gastric irritation,
stomach upset when administered orally. Thus various
approaches for solubility enhancement of irbesartan have been
reported which include formulation of nanocomposites [5],
solid dispersions [6], self emulsifying systems [7] and b,
c-cyclodextrin complexes [8,9]. There is lacuna in the literature
on the preparation of IBS-loaded transdermal nanofibre mats
to enhance its dissolution and permeation across the skin.
Formulation scientists have been working on development
of drug loaded nanofibres since they offer advantages such
as high ratio of surface area to mass or volume, high porosity
and extremely small pore size within fibres. Further, nanofibres
can be useful in targeting drug molecules to specific sites since
they present large possibilities for surface functionalization.
Electrospinning has been used most commonly to produce
drug loaded nanofibres owing to their advantages such as sim-
ple and continuous technique having ability to produce nanofi-
bres from a large variety of polymers with an ability ofindustrial scale-up [10]. In the electrospinning process, a suffi-
ciently high voltage is applied to a liquid droplet containing
polymer inducing the charge (positive or negative) in the same.
The droplet is stretched due to attraction by the oppositely
charged collector thus forming a stream of liquid from the sur-
face at a critical point which is known as the Taylor cone. The
charged liquid jet dries in flight leading to formation of fibres
which are collected on the rotating drum (collector) [11].
Considering the drawbacks associated with irbesartan and
the superiority of transdermal drug delivery, formulation of
irbesartan loaded nanofibre mat having an ability to provide
optimum amount of drug to control the disease condition with
minimum side effects is the need of hour. Further, it is believed
that such system can also lead to cost effectiveness of health-
care treatment for long-term management of hypertension
[12,13]. In current work, irbesartan loaded nanofibres of poly-
vinyl pyrrolidone (PVP) were prepared using electrospinning
technique and characterized for drug content, FTIR, DSC,
morphology, XRD, in vitro diffusion and ex vivo permeation
studies using Franz diffusion cell.
Material and methods
Materials
Irbesartan was generously gifted by Lupin Research Park,
Pune, India. Polyvinyl pyrrolidone (PVP K-30) was purchased
from Loba chemi, Mumbai, India. Methanol and N,
N-dimethylacetamide (DMAc) were purchased from S.D.
Lab and Labscan (Asia), Mumbai, India, respectively.
Methods
Preparation of spinning solutions
An accurately weighed PVP powder was dissolved in metha-
nol/DMAc (3:1 v/v) mixture to obtain a PVP solution (15%
w/v). Irbesartan (20% by weight of dry PVP) was added into
the base PVP solution under constant stirring for 4 h at
200 rpm (Heidolph mixer RZR 2051 control, Heidolph India,
Hyderabad, India).
Preparation of nanofibres
The prepared solutions were loaded in 5 mL syringe with 18
gauge needle (Resource Pharmaceuticals, Vadodara, India).
The feeding rate (0.5 mL/h) was controlled by a syringe pump.
A high voltage supply fixed at 12 kV was applied to the
metallic needle. A piece of aluminium foil kept at horizontal
Electrospun nanofibres of irbesartan with enhanced skin permeation 485distance of 15 cm from the needle tip was used to collect the
ultrafine fibres. The electrospinning process was carried out
under ambient conditions using an instrument E-Spin Nano
(PECO-Chennai, India). IBS loaded PVP films were also pre-
pared for comparison using solutions of similar composition
by solvent casting technique.
Characterization
Drug content and encapsulation efficiency (EE)
UV spectrophotometric method was used for quantification of
IBS loaded into PVP nanofibres and solvent cast films. To
describe in brief, the IBS loaded e-spun PVP fibre mats and
as cast IBS loaded films (cut into circular discs of 2.8 cm in
diameter) were dissolved in 5 mL of methanol separately.
The volume of each of the solution was made up to 10 mL with
7.4 pH phosphate buffer. Absorbance of each solution was
recorded at 224 nm using a UV spectrophotometer (Shimadzu
UV-1601, Kyoto, Japan) in order to obtain exact IBS content.
The results of drug content were used for determination of EE
using Eq. (1) [14]
%EE ¼Weight of irbesartan in the nanofibre mat or film
Total weight of irbesartan feeded
 100
ð1ÞScanning electron microscopy (SEM)
Scanning electron microscope (JEOL JSM-6360A, Tokyo,
Japan) was used to characterize morphology of both neat
and IBS loaded e-spun PVP fibre mats along with solvent cast
film separately. The fibre mat or film was mounted on alu-
minium stud separately and sputtered with a thin layer of plat-
inum using auto fine coater (Joel, JFC, Tokyo, Japan) prior to
observation. The average diameter of IBS loaded e-spun mats
was measured.
Differential scanning calorimetry (DSC)
Thermal behaviour of IBS, neat e-spun PVP mats and IBS
loaded nanofibre mats was analysed using a differential scan-
ning calorimeter (Mettler Toledo DSC 821e, Mettler-Toledo,
Greifensee, Switzerland). The samples (10–20 mg) were her-
metically sealed in aluminium crucibles separately and heated
at a constant rate of 10 C/min over a temperature range of
25–300 C [15]. Inert atmosphere was maintained by purging
nitrogen gas at a flow rate of 50 mL/min.
X-ray diffraction (XRD) analysis
Wide-angle X-ray diffraction analyses (XRD) of IBS alone,
IBS loaded nanofibre mats and IBS loaded as cast films were
carried out separately using a D/Max-BR X-ray diffractometer
(RigaKu, Tokyo, Japan). The samples were irradiated with Cu
Ka radiation and analysed in the 2h range of 5–60.
Fourier transform infrared spectroscopy (FTIR)
IBS alone, blank PVP nanofibres, IBS loaded nanofibre mats
and IBS loaded as cast films were analysed by Fourier trans-
form infrared spectroscopy (FT/IR4100, JASCO International
Co., Ltd., Tokyo, Japan). The samples were mixed with dry
potassium bromide (2 mg sample in 200 mg KBr) and placedin the mould. The IR spectra for the samples were recorded
in region from 4000 to 400 cm1.
In vitro drug diffusion studies
In vitro drug diffusion studies for dry IBS loaded nanofibre
mat and as cast film samples were performed using Franz dif-
fusion cell (Dolphin Instruments, Mumbai, India) with a reser-
voir capacity of 32 mL. Each of the samples was cut into
circular discs of 1.5 cm in diameter containing 50 mg of
IBS. The disc was placed in a donor compartment over the cel-
lophane membrane and covered with parafilm. The tempera-
ture of the receptor compartment containing phosphate
buffer pH 7.4 was maintained at 37 ± 2 C throughout the
experiment. The amount of IBS diffused through the mem-
brane was determined by withdrawing 1 mL of buffer from
the receptor compartment at a predetermined time interval
and replacing an equal volume of buffer thus ensuring sink
condition throughout the experiment. The samples were fil-
tered through Whatman filter paper and analysed spectropho-
tometrically at 224 nm for IBS content.
Ex vivo skin permeation studies
Ex vivo skin permeation studies were performed for IBS
loaded nanofibre mat and as cast film samples using Franz dif-
fusion cells fitted with excised rat skin [16]. Hairs on the
abdominal area of Wistar rat were shaved after its sacrification
by chloroform inhalation method. The subcutaneous tissue
was surgically removed from the skin upon excision from the
abdomen of the rat. Further, isopropyl alcohol was used for
wiping the dermis side of the skin so as to remove the residual
fat on its surface. Distilled water was then used for washing the
skin followed by treatment with 2 M sodium bromide solution
for 7 h. Finally, a cotton swab moistened with distilled water
was used for separating epidermis which was cleaned by wash-
ing with distilled water. The skin thus obtained was used for
permeation studies. The experimental protocol was approved
by the Animal Ethics Committee of Bharati Vidyapeeth University,
Poona College of Pharmacy, Pune (Approval no.: CPCSEA/
13P/2014). A vertical Franz diffusion cell having a surface
area of 2.54 cm2 and a reservoir capacity of 32 mL was used.
The receptor compartment was filled with phosphate buffer
pH 7.4 which was constantly stirred using magnetic stirrer
throughout the experiment. The temperature of the buffer
was maintained at 37 ± 1 C. IBS loaded nanofibre mats, as
cast films (IBS equivalent to 50 mg) and irbesartan alone
(50 mg) were applied on the epidermal surface of the skin sep-
arately. A media sample (2.5 mL) was withdrawn at a fixed
time intervals. Sink condition was maintained throughout
the experiment. The samples were filtered through Whatman
filter paper and analysed for IBS content using HPLC method
upon appropriate dilution. HPLC was used for quantification
of IBS because some of the skin components show absorbance
at 224 nm which may interfere with the results.
The HPLC system consisted of a chromatographic pump
(LC-20AT, Shimadzu, Kyoto, Japan) fitted with a UV detector.
For HPLC separation, a reversed-phase C18 column
(4.6  150 mm, micelle size 5 lm, Thermo Scientific,
Massachusetts, United States) was used. The mobile phase
was composed of acetonitrile: ammonium acetate buffer (pH
5.5) in a ratio of 30:70 with a flow rate of 1.5 mL/min. The run
time for analysis was 10 min and the detection wavelength was
486 R.N. Kamble et al.set at 235 nm. The mobile phase was filtered through 0.45 lm
millipore membrane filter and degassed by sonication (Bran-
sonic, CT, USA) before use. The sample injection volume was
20 lL. The retention time of IBS was found to be 7.2 min [17].
The cumulative amount of IBS permeated across skin (lg/
cm2) was plotted against time (min). The steady state flux ‘‘J”
(mcg cm2 h1) was determined from the slope of the linear
portion of the graph. Permeability Coefficient ‘‘Kp” (cm h1)
was calculated using Eq. (2),
Kp ¼ J=C0 ð2Þ
where C0 = concentration of drug in donor phase and
J= flux.
Results and discussion
The utility of water soluble polymers in enhancing solubility of
water insoluble drugs has been well documented in the litera-
ture. It is believed that these polymers act as stabilizers and
modify the surface of precipitated particles by hindering their
growth and preventing agglomeration. Various water soluble
polymers including HPMC, polyethylene glycols, cyclodextrins
and polyvinyl pyrrolidone (PVP) have been used for solubility
enhancement of poorly water soluble drugs [18]. In the present
work, PVP was used for preparation of nanofibres owing to its
inherent properties such as excellent physiological compatibil-
ity, and reasonable solubility in water along with other organic
solvents. Further, in the preliminary studies, PVP was found to
be effective in controlling the particle size and particle size dis-
tribution of IBS.
The solvent plays a key role in the successful preparation of
electrospun nanofibres. The solvent should dissolve the drug
easily while keeping electrospinnability of polymer solutions
intact. Amongst several individual and combinations of organic
solvents screened for solubilization of IBS andPVP, amixture of
methanol andDMAcwas found to be suitable.Moreover, it was
observed that the electrospinning process always proceeded un-
interruptedwhen using thismixturewhich could be attributed to
the high boiling point of DMAc favouring formation of a stable
Taylor cone and preventing spinneret clogging through preven-
tion of gel-formation at the jet surface [19]. Thus the current
work involved preparation of IBS loaded PVP nanofibres using
electrospinning method. The prepared fibres were investigated
for morphology and dimensions.Fig. 1 SEM images of (A) IBS loaded nanofibres at 10,000, (B) IBS
at 10,000.SEM of IBS loaded PVP fibre mats
SEM was used in order to confirm formation of nanofibres
(Fig. 1). SEM images revealed formation of discrete IBS
loaded PVP nanofibres having size in the range of 60–80 nm.
Since the images did not show the presence of the drug crystals
and/or aggregates it is postulated that the drug was encapsu-
lated and molecularly dispersed within the electrospun fibres.
This is in contrast to the IBS loaded solvent cast film which
showed the presence of drug crystals on its surface. The non-
existence or the existence of the drug aggregates on the surface
of the fibres or films could also be due to the difference in the
evaporation rate of the solvents (methanol and DMAc) during
fabrication. The evaporation of the solvents from the fibres
occurred in an extremely short time (i.e. during their flight to
the collecting device). On the other hand, the evaporation of
the solvent from the films occurred slowly. The longer time
for evaporation of the solvent from the drug-loaded as cast
films could be responsible for the observation of the drug
aggregates on their surface [20].
X-ray diffraction studies
X-ray diffraction analysis of the prepared samples was
performed in order to assess the polymorphic transitions (if
any) that might have been taken place in IBS when formulated
as nanofibres. Further, XRD patterns can also be used to eval-
uate the degree of crystallinity of sample using the relative inte-
grated intensity of reflection peaks in the given range of
reflecting angle 2h.
XRD patterns of IBS alone, as cast film and IBS loaded
nanofibres are shown in Fig. 2. The XRD pattern of IBS alone
exhibits intense peaks at 2h angles of 4.97, 9.35, 12.41,
16.92, 19.30, and 23.05 which reveal its crystalline nature
[21]. However, diffractogram of IBS loaded nanofibres showed
broad and diffuse maxima peaks which may be attributed to
the amorphization of IBS when formulated as nanofibres. It
has been well reported that the amorphous solid state of a
compound possesses several advantages including enhanced
solubility, improved wettability and increased dissolution rate
to its crystalline counterpart. IBS loaded as cast films retained
the peaks which were attributed to the crystalline IBS indicat-
ing existence of IBS in crystalline form.loaded nanofibres at 30,000 and (C) IBS loaded solvent-cast films
Fig. 2 XRD analysis of irbesartan, irbesartan loaded nanofibres
and as cast films.
Fig. 4 FTIR spectra of (A) irbesartan, (B) PVP, (C) IBS-loaded
nanofibre mats and (D) IBS-loaded as-cast films.
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DSC thermograms of prepared samples supported the results
of XRD studies (Fig. 3). DSC is a tool used to measure the
temperature and energy variation involved in the phase transi-
tions of the compound which in turn helps to reveal degree of
crystallinity associated with it. IBS alone showed sharp
endothermic peak at 188.9 C (with an enthalpy of 97.3 J/g)
corresponding to its melting point confirming its crystalline
nature. The DSC thermogram of PVP K-30 showed a broad
endotherm at 92.62 C which is indicative of loss of water by
extremely hygroscopic PVP polymer chains.
IBS loaded as cast film showed melting endotherms at
90.13 C and 184.7 C which is self indicative of existence of
IBS in crystalline form and the result was in accordance with
XRD analysis. However, IBS loaded nanofibre mat showed
a single endothermic peak at 91.52 C. Additionally, peak
associated with IBS melting point was absent indicating its
complete amorphization when formulated as nanofibres [22].
Thus results of DSC studies were in accordance with the
XRD analysis.
Fourier transformed infrared spectroscopy (FTIR)
FTIR spectra were recorded for IBS alone, IBS loaded as cast
films and IBS loaded nanofibres (Fig. 4). IBS alone showedFig. 3 Differential scanning calorimetric thermograms of irbe-
sartan, PVP-K30, IBS-loaded as cast film and nanofibres.sharp characteristic bands at 3436.51 cm1 (NAH stretching),
2960.52 cm1 (CAH stretching), 1733.30 cm1 (C‚O stretch-
ing), 1485.77 cm1 (C‚C stretching) and 1614.83 cm1
(NAH bending). The IR spectrum of PVP K-30 showed char-
acteristic bands at 3435 cm1 (OAH), 2955 cm1 (CAH
stretch) and 1654 cm1 (C‚O) [23,24].
The spectra of IBS loaded nanofibres and as cast film
showed retention of all the characteristics bands of IBS and
PVP. Further, there was no predominant shifting of existing
bands or appearance of new bands suggesting compatibility
of IBS with PVP due to the absence of any chemical
interaction.
Drug content and encapsulation efficiency
IBS content in the prepared e-spun PVP nanofibres was found
to be 82.62 ± 2.1%w/w whereas solvent cast films showed IBS
loading of about 64.8 ± 1.21%w/w. Additionally, the EE of
e-spun PVP nanofibres was found to be 97.13 ± 1.38%w/w
whereas solvent cast films showed EE of about 78.8
± 2.13%w/w. The films were casted at higher temperature
(70 ± 1 C) so as to remove the solvent completely. It is well
reported in the literature that IBS degrades at high tempera-
ture. Such thermal degradation of IBS might have been
responsible for reduction in the drug content of solvent cast
films [17].
In vitro IBS diffusion studies
The IBS release from the nanofibre mats and as cast film was
performed in phosphate buffer pH 7.4 and compared to release
curve of IBS powder (Fig. 5). IBS loaded e-spun nanofibre mat
showed 89.91 ± 1.87% release after 4 h whereas the as cast
film showed IBS release of about 71 ± 1.6% after 8 h.
Diffusion of IBS alone was found to be 32 ± 1.24% after
8 h confirming its low solubility in phosphate buffer pH 7.4.
The slower rates and the lower maximum amount of IBS
released from IBS loaded as cast films in comparison with
those from the nanofibre counterparts could be attributed to
Fig. 5 In vitro diffusion study of IBS loaded nanofibres and
as-cast films.
Fig. 6 Skin permeation profile of IBS-loaded nanofibres and as-
cast films.
Table 1 Skin permeation kinetics of irbesartan from IBS





Flux 5.01 ± 0.38 0.301 ± 0.23
Permeability 0.00482 0.000588
Mean ± SD.
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films. The slow swelling of film resulted in slow diffusion of
IBS from the polymer matrix. Additionally, IBS aggregates
were formed on the film surface which might have dissolved
to a lesser extent. On the contrary, nanofibres contained
non-aggregated IBS in amorphous state which has been
reported to have high solubility than crystalline form. The
enormously increased surface area for dissolution, amorphiza-
tion of IBS and the absence of IBS aggregates might be respon-
sible for the improvement in the diffusion of IBS when
formulated as nanofibres. The analogy of drug diffusion
through swollen polymer matrix was confirmed from the IBS
release curves of nanofibres mats and as cast films. The curves
were subjected to model fitting consisting of various models
such as zero order, first order, Higuchi, Hixson–Crowell and
Korsmeyer–Peppas model [25]. Both the release curves fol-
lowed Kormeyer–Peppas model (R2 = 0.998) which express
diffusion controlled release of drug as expressed by Eq. (3)
confirming diffusion of IBS through swollen polymer matrix
as suggested previously [26].
Q ¼ ktn ð3Þwhere Q is the percentage of drug released at time t, k is a
kinetic constant and n is the diffusional exponent indicative
of the release mechanism. When the value of n= 0.5 indicates
Fickian diffusion, values below 0.5 suggest non-Fickian trans-
port of drug.
The diffusion exponent ‘n’ was 0.5003 and 0.3237 for IBS
loaded nanofibres and as cast film respectively. The ‘n’ value
for IBS loaded nanofibre mats indicates that the IBS release
follows Fick’s law of diffusion. Drug release from as cast film
was likely to be controlled by a combination of diffusion and
erosion mechanisms [26]. Permeation of the drug from a trans-
dermal drug delivery system mainly involves the factor of
diffusion.
Ex vivo skin permeation
The ex vivo skin permeation data revealed superiority of IBS
loaded nanofibres mats over as cast films (Fig. 6, Table 1) since
the flux of nanofibres mats was 17 times greater than that of as
cast film. Further, the permeability coefficient was also found
to be greater for nanofibres as compared to the films. The
superiority of nanofibre mats over as cast films may be attrib-
uted to the solubility improvement of IBS due to molecular
dispersion within PVP, fast swelling of porous nanofibres mats
due to small size and enormous increase in the area ultimately
leading to leaching out of IBS molecules at a faster rate when
compared to as cast films. Additionally, linear increment in the
permeation flux with increase of IBS in both IBS loaded
nanofibre mats and as cast PVP films was observed. This
may be attributed to the reduction in the relative amount of
polymer which acts as a diffusion barrier for IBS resulting in
increased IBS release. Thus the higher concentration gradient
provided the greater permeation of IBS from the nanofibre
mats.
Conclusions
In the present work, IBS loaded nanofibre mats were success-
fully prepared using electrospinning technique. The prepared
nanofibre mats of IBS were found to be superior to IBS loaded
as cast films when analysed for in vitro IBS release and ex vivo
skin permeation studies. The improvement in drug delivery
kinetics of IBS loaded nanofibre mats could be attributed to
amorphization with reduction in particle size of IBS, disper-
sion of IBS at molecular level in PVP matrix and enormous
increase in the area for IBS dissolution due to nanonization
as revealed by SEM, XRD and DSC studies. Hence,
transdermal patch of IBS loaded nanofibres can be considered
as an alternative dosage form in order to improve its
biopharmaceutical properties and enhance therapeutic efficacy
in hypertension.
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